Introduction
Blind loop syndrome (BLS), or stagnant loop syndrome, is a rare malabsorptive disorder with growing clinical significance in gastroenterology. This disease can evolve as a complication from multiple pathologies, including anatomic abnormalities, motility disorders, and inflammatory disease. This condition is further defined by its distinctive pathogenesis: stagnation of the small intestine causing pathologic bacterial overgrowth.[1]
Under normal circumstances, the small bowel harbors a sparse amount of mixed flora in concentrations of less than 1,000 microorganisms/mL. However, static conditions can alter the population dynamic. In blind loop syndrome, stasis enables the proliferation of species like Bacteroides, E. coli, Streptococcus, and Lactobacillus in abnormally high concentrations. Consequently, this overgrowth affects digestion and absorption, resulting in malnutrition, B12 deficiency, and steatorrhea.[2][3]
Etiology
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Anatomic Abnormalities (most prevalent)
- Afferent loop syndrome (most commonly from Billroth II, Roux-en-Y, Whipple procedure) [4]
- Surgical complications (fistulas, strictures, scarring)
- Anastomosis
- Jejunal diverticulosis
Motility Disorders
- Scleroderma
- Parkinson disease
- Diabetic gastroparesis [5]
Inflammatory Disease
- Crohn disease
- Radiation enteritis
- Diverticulitis
- Celiac disease [6]
Epidemiology
There is insufficient epidemiological data, as the patient presentation can be vague, and the diagnosis is infrequently worked up or mistaken for alternative diagnoses.
Pathophysiology
The etiologies of this disease process, as mentioned above, can cause stasis in a segment of the proximal small intestine. This dysfunction impairs peristaltic motility and impedes luminal flow. Throughout digestion, food is diverted around the stagnant length of the bowel, suitably called the “blind loop.” Naturally, particulate builds up, serving as a focal point for bacterial proliferation.
The consensus of current literature points to Bacteroides, E. coli, Streptococcus, and Lactobacillus as the implicating species in BLS.[7] However, there is debate on how these organisms disrupt cobalamin absorption to manifest this constellation of symptoms. One theory suggests that bacteria (ie, Bacteroides) directly injure the alimentary tract through released toxins or harmful by-products of microbial metabolism.[8] Another theory proposes that microbes (ie, E coli and Streptococcus) remove the available supply of vitamin B12 from the lumen for use during replication.[9]
In addition to restricting the absorption of B12, microbial overgrowth also impairs fat absorption. Under normal conditions, conjugated bile salts are transported into the duodenum to solubilize dietary lipids. As food passes through the gut, the intestinal flora deconjugates a small percentage of bile salts/acids, which exit the body through the stool. However, in stagnant conditions, the population of bacteria drastically increases. Accordingly, more bacteria (notoriously anaerobes) yield more unconjugated bile salts/acids, manifesting as steatorrhea and fat-soluble deficiencies.[10][11]
Histopathology
The blind loop histology exhibits patterns that deviate from the prototypical mucosa. Specifically, affected tissues display villous and crypt gland hypertrophy. Vesiculated columnar cells can also be seen in a fraction of the villi. Furthermore, affected segments display epithelial damage without evidence of direct bacterial infiltration.[12] Sometimes, a loss of enzymatic activity at the brush border can result in acquired lactase deficiency.[13]
History and Physical
A comprehensive history and thorough physical exam are essential, as the presentation is often vague and variable amongst patients. Inquiring about recent surgical history or comorbidities may provide the insight needed to recognize this condition. Although it can be challenging to identify, listed below are the symptoms most commonly associated with BLS:
Megaloblastic Anemia
It typically results from vitamin B12 deficiency; sometimes multifactorial, seen in conjunction with low folate levels.[14]
Diarrhea/Steatorrhea
The specific presentation depends on the etiology, region, and extent of bowel involvement; diarrhea/steatorrhea also contributes to weight loss.[15]
Malnutrition
Patients can develop multiple micronutrient deficiencies due to intestinal damage and impaired fat absorption.[16] Unabsorbed fatty acids may also bind to dietary calcium, inducing hypocalcemia. Listed below are varying ways in which these deficiencies may present:
- Vitamin A deficiency: xeropthalmia, night blindness, hyperkeratosis
- Vitamin D deficiency: secondary hyperparathyroidism, muscle weakness, fractures
- Vitamin K deficiency: bruising, melena, hematuria, menorrhagia
- Vitamin E deficiency: neuropathy, nystagmus, skeletal myopathy
- Calcium deficiency: brittle bones, seizures, prolonged QT interval
Protein Loss
It can be seen as cachexia or edema on physical exam.[17]
Other non-specific symptoms include diffuse, crampy, and colicky abdominal pain, nausea, belching, bloating, and flatulence.
Evaluation
Radiologic Imaging
Diagnostic imaging is a practical method for evaluating a blind loop. Applicable radiologic studies include x-rays, computerized tomography (CT) scans, barium series, and CT enterography. Although abdominal films and CT scans are simple and cost-effective modalities, they have limited utility in the context of this syndrome. Accordingly, evidence of obstruction or dilatation on X-ray/CT should prompt further workup when BLS is suspected.
Barium studies are beneficial as they provide added information concerning the structure and motility of the bowel. In addition to assessing transit time, they can detect aberrations like jejunal diverticula, intestinal strictures, and fistulas. Ultimately, CT enterography is the superior test for identifying mechanical causes of overgrowth. Although similar to the barium series, it is more sensitive and provides greater detail.[7][18]
Breath Tests and Cultures
If there is high clinical suspicion of blind loop syndrome, it is valid to consider ordering additional testing. A sensible workup may include a qualitative fecal fat test, hydrogen breath test, D-xylose absorption test, bile acid breath test, or small bowel aspiration.
Initially, testing for fecal fat is an appropriate first step, as it can confirm the presence of malabsorption; otherwise, it has limited diagnostic relevance in this condition. Next, the hydrogen breath test and its more accurate counterpart, the D-xylose absorption test, are applicable for detecting the presence of bacterial overgrowth. However, neither is notably useful for expressly identifying blind loop syndrome.[19]
Alternatively, the bile acid breath test is more specific, assessing for both bacterial overgrowth and bile acid malabsorption. Overall, it is a simple and effective test.[20][21] To establish a definitive diagnosis, it is necessary to quantify cultures from a small bowel aspirate. Regardless, this procedure is uncommon for diagnostic confirmation as acquiring these cultures can be invasive, costly, and time-consuming.[22]
The Schilling Test
Of note, the Schilling test was once widely used to confirm the presence of a blind loop. In this test, medical professionals assessed urinary cobalamin. Excretory patterns mirrored those of pernicious anemia but would correct with the addition of antibiotics. Regardless of its benefit in BLS, most medical centers have deemed this test obsolete, and no substitute exists.
Treatment / Management
Medical Management
The primary objectives for managing blind loop syndrome are reducing bacterial overload, correcting related deficiencies, and managing unwanted symptoms. Historically, the standard of care for bacterial eradication has been a single course of empiric antibiotics. In the past, physicians routinely prescribed 1 of the tetracyclines, as they have strong anaerobic coverage. While effective, recent studies have shown improved efficacy in alternative therapies, namely rifaximin and metronidazole.[23][24] The recommended duration of therapy ranges from 7-10 days. While a single course is often sufficient, recurrence is uncommon. In such cases, physicians may try switching treatments to prevent microbial resistance.(A1)
Surgical Management
Surgical intervention is an option for blind loops with anatomic etiologies. It can also benefit patients with refractory cases requiring multiple rounds of antibiotics. The intended goal of surgery is to address the underlying defect, resect blind loops with significant hypertrophy, and re-establish a functional gastrointestinal tract. If a stricture and non-functional loop are present, stricturoplasty or resection is indicated. In the case of anastomotic blind loop syndrome, the blind loop should be resected, and the anastomosis remade. In patients who develop stagnancy after undergoing a Billroth II, there is evidence of successful conversion to a Billroth I; in this instance, the duodenum is involved and should not be resected.[7]
Nutritional Care
Nutritional care aims to prevent negative outcomes by correcting underlying deficiencies. Nourishment is especially critical in those with considerable weight loss. While individual needs may vary, nutritionists recommend a high-calorie, low-fat diet. Depending on the extent of disease progression, patients may also require intramuscular B12, oral vitamins, or minerals supplementation. Ultimately, it is also the physician’s role to counsel patients with acquired lactase deficiencies.
Differential Diagnosis
Irritable bowel syndrome (IBS) is a functional condition with a poorly understood pathophysiology. Patients typically complain of abdominal pain that improves with defecation, changes in stool frequency, and altered stool consistency. Although it presents similarly, IBS does not have the accompanying deficiencies seen in BLS.[25]
Celiac disease is an autoimmune pathology marked by blunting of the duodenal villi. Symptoms include chronic diarrhea, bloating, weight loss, and vitamin B12 deficiency. Although comparable to blind loop syndrome, celiac disease has distinguished tissue transglutaminase antibodies elicited in response to gluten consumption.[26]
Tropical sprue is a malabsorptive illness with a suspected infectious etiology - as in BLS, patients present with diarrhea or steatorrhea and a vitamin B12 deficiency. However, Tropical Sprue has a unique geographical distribution and distinctive mucosal histology.[27]
Whipple disease is another malabsorptive illness resulting in weight loss, diarrhea, steatorrhea, and other non-specific symptoms of indigestion. On physical exam, patients may present with altered mental status, arthralgias, and lymphadenopathy. A mucosal biopsy exhibiting T whipplei establishes a definitive diagnosis.[28]
Pancreatic insufficiency is a disorder where the pancreatic exocrine function is impaired. People with a history of pancreatitis may present with steatorrhea, weight loss, and fat-soluble deficiencies. A D-xylose test can help to differentiate Pancreatic Insufficiency from blind loop syndrome by assessing the integrity of the gastrointestinal mucosa.[29]
Crohn disease is an inflammatory bowel pathology characterized by non-caseating granulomas and transmural inflammation. It commonly involves the terminal ileum, resulting in watery diarrhea, steatorrhea, and vitamin B12 deficiency. In contrast to BLS, Crohn disease can also exhibit extra-intestinal manifestations, including uveitis and erythema nodosum. A colorectal biopsy is required to confirm this diagnosis.[30]
Prognosis
The prognosis of BLS depends on the etiology and extent of disease progression.
Complications
Subacute Combined Degeneration
Subacute combined degeneration is a dangerous neurological complication of blind loop syndrome. As stated above, excessive intestinal overgrowth limits the capacity of cobalamin absorption. Over time, prolonged B12 deficiency leads to demyelination of the dorsal column-medial lemniscus pathway. This condition presents with paresthesia, ataxia, and a loss of positional sense. Left untreated, it may result in severe symptoms like spasticity or paraplegia.[31]
Osteomalacia
Osteomalacia is another reported sequela of blind loop syndrome. In this pathology, prolonged vitamin D deficiency from fat malabsorption results in bone demineralization. Symptoms can manifest as aching bone pain, arthralgias, or proximal muscle weakness. Recognizing and treating this disease is critical to preventing insufficiency fractures.[32][33]
Retroperitoneal Hemorrhage
Retroperitoneal hemorrhage is a rare but potentially life-threatening surgical sequela of blind loop syndrome. Physiologically, fat malabsorption depletes vitamin K stores. This deficit stunts the production of prothrombin, resulting in a hypocoagulable state. During surgery, patients can develop uncontrolled intraoperative bleeding and eventual hemorrhagic shock. Considering this complication before surgical intervention is crucial, as the mortality rate is about 18%.[14][34]
Deterrence and Patient Education
Educating at-risk populations on the presentation of this disease is vital. Effective instruction can expedite the diagnostic process, ultimately preventing illness progression. Furthermore, this simple measure can significantly reduce disease prevalence and post-op morbidity in patients status post gastrointestinal surgery.
Enhancing Healthcare Team Outcomes
Blind loop syndrome causes anemia, steatorrhea, and variable micronutrient deficiencies. Proper management can majorly impact a patient's quality of life. Conversely, mismanagement or delayed treatment can result in numerous complications. Improving the coordination between nurses, pharmacists, and physicians ultimately enhances the quality of patient-centered care.
Clinicians play an integral role in managing blind loops. They are responsible for drawing blood, administering antibiotics or other symptomatic therapies, and providing competent health education to the patient. Nurses, as they maintain the most contact with the patient, can also advise the physician on disease progression.
Ultimately, the physician is in charge of guiding the team's efforts. They do so by ordering appropriate tests and medicines and monitoring the patient's status and clinical improvement. Furthermore, physicians are in charge of consulting gastroenterology or general surgery when indicated.
Pharmacists work alongside physicians to maintain positive patient outcomes. They can advise on intelligent antibiotic selection to ensure adequate anaerobic coverage and inform providers of potential drug interactions. Managing and treating blind loop syndrome can be a complex task. This operation requires a high standard of ethics and open communication. Favorable patient outcomes ultimately depend on the collective efforts of the interprofessional healthcare team.
References
CARD WI. Blind loop syndrome. Proceedings of the Royal Society of Medicine. 1959 Jan:52(1):28-31 [PubMed PMID: 13623846]
Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Digestive diseases and sciences. 2008 Jun:53(6):1443-54 [PubMed PMID: 17990113]
Level 1 (high-level) evidenceTabaqchali S. The microflora of the stagnant loop syndrome. Proceedings of the Royal Society of Medicine. 1969 Oct:62(10):981 [PubMed PMID: 4899509]
Blouhos K,Boulas KA,Tsalis K,Hatzigeorgiadis A, Management of afferent loop obstruction: Reoperation or endoscopic and percutaneous interventions? World journal of gastrointestinal surgery. 2015 Sep 27; [PubMed PMID: 26425267]
Losurdo G, Salvatore D'Abramo F, Indellicati G, Lillo C, Ierardi E, Di Leo A. The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. International journal of molecular sciences. 2020 May 16:21(10):. doi: 10.3390/ijms21103531. Epub 2020 May 16 [PubMed PMID: 32429454]
La Barbera L, Macaluso F, Fasano S, Grasso G, Ciccia F, Guggino G. Microbiome Changes in Connective Tissue Diseases and Vasculitis: Focus on Metabolism and Inflammation. International journal of molecular sciences. 2022 Jun 10:23(12):. doi: 10.3390/ijms23126532. Epub 2022 Jun 10 [PubMed PMID: 35742974]
STARZL TE, BUTZ GW Jr, HARTMAN CF. The blind-loop syndrome after gastric operations. Surgery. 1961 Nov:50():849-58 [PubMed PMID: 13916392]
Riepe SP,Goldstein J,Alpers DH, Effect of secreted Bacteroides proteases on human intestinal brush border hydrolases. The Journal of clinical investigation. 1980 Aug; [PubMed PMID: 6995483]
BURKHOLDER PR. Microbiological studies on materials which potentiate oral vitamin B12 therapy in Addisonian Anemia. Archives of biochemistry and biophysics. 1952 Aug:39(2):322-32 [PubMed PMID: 12997167]
Northfield TC. Intraluminal precipitation of bile acids in stagnant loop syndrome. British medical journal. 1973 Jun 30:2(5869):743-5 [PubMed PMID: 4718317]
Masuda N. Deconjugation of bile salts by Bacteroids and Clostridium. Microbiology and immunology. 1981:25(1):1-11 [PubMed PMID: 6265737]
Toskes PP, Giannella RA, Jervis HR, Rout WR, Takeuchi A. Small intestinal mucosal injury in the experimental blind loop syndrome. Light- and electron-microscopic and histochemical studies. Gastroenterology. 1975 May:68(5 Pt 1):1193-203 [PubMed PMID: 1126607]
Level 3 (low-level) evidenceGiannella RA, Rout WR, Toskes PP. Jejunal brush border injury and impaired sugar and amino acid uptake in the blind loop syndrome. Gastroenterology. 1974 Nov:67(5):965-74 [PubMed PMID: 4426497]
Level 3 (low-level) evidenceBADENOCH J. The blind loop syndrome. Proceedings of the Royal Society of Medicine. 1960 Aug:53(8):657-8 [PubMed PMID: 13795649]
ELLIS M. DIARRHOEA OF SMALL BOWEL ORIGIN. THE BLIND LOOP SYNDROME. Proceedings of the Royal Society of Medicine. 1963 Dec:56(12):1081-2 [PubMed PMID: 14098555]
Montoro-Huguet MA, Belloc B, Domínguez-Cajal M. Small and Large Intestine (I): Malabsorption of Nutrients. Nutrients. 2021 Apr 11:13(4):. doi: 10.3390/nu13041254. Epub 2021 Apr 11 [PubMed PMID: 33920345]
Jones EA, Craigie A, Tavill AS, Franglen G, Rosenoer VM. Protein metabolism in the intestinal stagnant loop syndrome. Gut. 1968 Aug:9(4):466-9 [PubMed PMID: 5677282]
Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Therapeutic advances in chronic disease. 2013 Sep:4(5):223-31. doi: 10.1177/2040622313496126. Epub [PubMed PMID: 23997926]
Level 3 (low-level) evidenceCasellas F, Chicharro L, Malagelada JR. Potential usefulness of hydrogen breath test with D-xylose in clinical management of intestinal malabsorption. Digestive diseases and sciences. 1993 Feb:38(2):321-7 [PubMed PMID: 8425444]
Level 3 (low-level) evidenceFromm H, Hofmann AF. Breath test for altered bile-acid metabolism. Lancet (London, England). 1971 Sep 18:2(7725):621-5 [PubMed PMID: 4105944]
Farivar S, Fromm H, Schindler D, Schmidt FW. Sensitivity of bile acid breath test in the diagnosis of bacterial overgrowth in the small intestine with and without the stagnant (blind) loop syndrome. Digestive diseases and sciences. 1979 Jan:24(1):33-40 [PubMed PMID: 428288]
Goldstein F, Mandle RJ, Schaedler RW. The blind-loop syndrome and its variants. Microbiologic aspects of diagnosis and treatment. The American journal of gastroenterology. 1973 Sep:60(3):255-64 [PubMed PMID: 4583160]
Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Alimentary pharmacology & therapeutics. 2000 May:14(5):551-6 [PubMed PMID: 10792117]
Level 1 (high-level) evidenceDi Stefano M, Miceli E, Missanelli A, Mazzocchi S, Corazza GR. Absorbable vs. non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. Alimentary pharmacology & therapeutics. 2005 Apr 15:21(8):985-92 [PubMed PMID: 15813834]
Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet (London, England). 2020 Nov 21:396(10263):1675-1688. doi: 10.1016/S0140-6736(20)31548-8. Epub 2020 Oct 10 [PubMed PMID: 33049223]
Rubin JE, Crowe SE. Celiac Disease. Annals of internal medicine. 2020 Jan 7:172(1):ITC1-ITC16. doi: 10.7326/AITC202001070. Epub [PubMed PMID: 31905394]
Brar HS, Aloysius MM, Shah NJ. Tropical Sprue. StatPearls. 2024 Jan:(): [PubMed PMID: 33620819]
Antunes C, Singhal M. Whipple Disease. StatPearls. 2024 Jan:(): [PubMed PMID: 28722966]
Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World journal of gastroenterology. 2013 Nov 14:19(42):7258-66. doi: 10.3748/wjg.v19.i42.7258. Epub [PubMed PMID: 24259956]
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet (London, England). 2017 Apr 29:389(10080):1741-1755. doi: 10.1016/S0140-6736(16)31711-1. Epub 2016 Dec 1 [PubMed PMID: 27914655]
Saji AM, Lui F, De Jesus O. Spinal Cord Subacute Combined Degeneration. StatPearls. 2024 Jan:(): [PubMed PMID: 32809563]
Schjonsby H. Osteomalacia in the stagnant loop syndrome. Acta medica Scandinavica. Supplementum. 1977:603():39-41 [PubMed PMID: 266835]
Level 3 (low-level) evidenceZimmerman L, McKeon B. Osteomalacia. StatPearls. 2024 Jan:(): [PubMed PMID: 31869080]
Dorosh J, Lin JC. Retroperitoneal Bleeding. StatPearls. 2024 Jan:(): [PubMed PMID: 33085330]